Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website
Subscribe CustomBlackClose

Belt & Road Weekly Subscription Form

download_pop

Research ReportCustomBlackClose

The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.

Click on the button below to create your account and get immediate access to thousands of articles.

Start a Free Trial

Xinhua Silk Road
Company

Jiuzhitang (000989.SZ): new drug approved by U.S. FDA for clinical trials

July 19, 2021


Abstract : Jiuzhitang Co., Ltd. (000989.SZ), a leading Chinese company engaged in the traditional Chinese medicine (TCM), announced on Sunday evening that a new drug developed by its wholly subsidiary has been approved by the U.S. Food and Drug Administration (FDA).


Jiuzhitang.png

BEIJING, July 19 (Xinhua) -- Jiuzhitang Co., Ltd. (000989.SZ), a leading Chinese company engaged in the traditional Chinese medicine (TCM), announced on Sunday evening that a new drug developed by its wholly-owned subsidiary has been approved by the U.S. Food and Drug Administration (FDA).

It means that the new drug can be used for clinical trials in the United States.

It is reported that the new drug called YB209 is a new type of anticoagulant derived from marine organisms with structural modification.

The company owns the independent intellectual property for the new drug and has already obtained related patent certificates in eight countries. (Edited by Hu Pingchao, Huang Yurong with Xinhua Silk Road, hupingchao@xinhua.org)

Scan the QR code and push it to your mobile phone

Keyword: TCM Jiuzhitang

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to [email protected] and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial

Ask Us A Question belt & road login close

If you have any questions, please enter them in the box below.

Identifying code Reload

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial